Full Text View
Tabular View
No Study Results Posted
Related Studies
Vaccine Therapy in Treating Patients With Primary Stage II Melanoma
This study is ongoing, but not recruiting participants.
Study NCT00005052   Information provided by National Cancer Institute (NCI)
First Received: April 6, 2000   Last Updated: February 6, 2009   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Melanoma (Skin)
Additional conditions recognized in this trial
Melanoma
More general conditions related to this trial
Neoplasms
Neoplasms by Histologic Type
Neoplasms, Germ Cell and Embryonal
Neoplasms, Nerve Tissue
Neuroectodermal Tumors
Neuroendocrine Tumors
Nevi and Melanomas
Interventions listed in this trial
GM2-KLH vaccine
QS21
adjuvant therapy
Additional drug interventions recognized in this trial
Adjuvants, Immunologic
QS 21
More general drug interventions related to this trial
Immunologic Factors
Pharmacologic Actions
Physiological Effects of Drugs
Sponsors listed in this trial
European Organization for Research and Treatment of Cancer


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services